Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Ricerca sui Probiotici: Intervento Funzionale in Aperto e Valutazione Longitudinale in Adulti Sani (PROFILE)

16 settembre 2026 aggiornato da: OneCarbon

This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.

During the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.

This study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Aged 18 years or older at the time of providing informed consent.
  • In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.
  • No history of significant psychiatric or neurological illness
  • Ability to complete study specific tasks, including:
  • Daily oral intake of a probiotic capsule
  • Self-collection of stool samples
  • Completion of online questionnaires and simple cognitive tasks
  • Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.
  • Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.

Exclusion Criteria:

  • Participants will be excluded from the study if any of the following criteria apply:
  • Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:
  • β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals
  • Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:
  • Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.
  • A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.
  • Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.
  • Major gastrointestinal disease or surgery:
  • Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.
  • Current pregnancy or development of pregnancy, breastfeeding
  • Known allergy to probiotic or compounding ingredients:
  • Vitamin D3
  • Isomaltooligosaccharide
  • Yeast extract

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Short Phase Group

This group will receive supplementation for 1 month

This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked.

Sperimentale: Long Phase Group

This group will receive supplementation for 6 months

This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in metagenome of stool samples
Lasso di tempo: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

The investigators will evaluate changes in genetic material in participant stool, representing establishment of the probiotic in the digestive tract

From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in blood multiome
Lasso di tempo: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

This measure will evaluate change in blood proteins (plasma proteome) and blood metabolites (plasma metabolome). Both measures are quantified using mass to charge ratio.

From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
Changes in cognition
Lasso di tempo: Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.

Participants will complete a weekly online cognitive test administered via our remote platform. This generates a score relativised to each participant's performance, and does not utilise a scale.

Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
Change in daytime sleepiness
Lasso di tempo: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will complete the Epworth Sleepiness Scale (ESS), with a minimum score of 0, and a maximum score of 24. A higher score indicates worse daytime sleepiness.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Change in sleep quality
Lasso di tempo: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will complete the Pittsburgh Sleep Quality Index (PSQI) survey. This has a minimum global score of 0, and a maximum of 21. A higher score indicates worse sleep quality.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Change in self-reported wellbeing and mood
Lasso di tempo: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will fill out a questionnaire at the beginning and end of the study which will ask questions about subjective mood and wellbeing.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Adverse event monitoring
Lasso di tempo: Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.

Participants will be expected to self-report any adverse features resulting from use of the supplement

Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2027

Completamento primario (Stimato)

1 luglio 2027

Completamento dello studio (Stimato)

1 luglio 2027

Date di iscrizione allo studio

Primo inviato

25 febbraio 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 marzo 2026

Primo Inserito (Effettivo)

9 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • PROFILE

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

All personal data collected during the study will be pseudonymised at the earliest possible stage. Each participant will be assigned a unique study ID number, which will be used on all samples, questionnaires, and datasets. A separate, password-protected file will securely store the link between participant names and study IDs. This file will be accessible only to authorised study personnel.

No identifiable personal information will be included in the research database or shared with external analysts. All electronic data will be stored on secure, encrypted servers in compliance with UK GDPR and the Data Protection Act 2018. Access will be limited to members of the research team through password-protected accounts and role-based permissions.

Hard copies of personal data will not be collected or stored. Any correspondence containing identifiable information (e.g. email addresses) will be deleted or anonymised once no longer needed.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .